Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY1R | P25929 | 1/20 | 0.62 |
| ▸ | NPY2R | P49146 | 1/20 | 0.62 |
| ▸ | NPY4R | P50391 | 1/20 | 0.62 |
| ▸ | NPY5R | Q15761 | 1/20 | 0.62 |
| ▸ | AGTR1 | P30556 | 2/20 | 0.58 |
| ▸ | AGTR2 | P50052 | 2/20 | 0.58 |
| ▸ | GLP1R | P43220 | 13/20 | 0.58 |
| ▸ | MC4R | P32245 | 2/20 | 0.57 |
| ▸ | MC5R | P33032 | 2/20 | 0.57 |
| ▸ | MC3R | P41968 | 2/20 | 0.57 |
| ▸ | MC1R | Q01726 | 2/20 | 0.57 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.56 |
| ▸ | ECE1 | P42892 | 1/20 | 0.56 |
| ▸ | MUS81 | Q96NY9 | 1/20 | 0.56 |
| ▸ | PRLHR | P49683 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29496930 | 1.00 | NPY1R (0.62) | NPY1RNPY2RNPY4RNPY5RAGTR1 | |
| SCHEMBL22872738 | 0.97 | NPY1R (0.61) | NPY1RNPY2RNPY4RNPY5RAGTR1 | |
| SCHEMBL31038378 | 0.92 | NMBR (0.63) | GLP1R | |
| SCHEMBL25460022 | 0.90 | NMBR (0.63) | NPY1RNPY2RNPY4RNPY5RGLP1R | |
| SCHEMBL30891928 | 0.90 | NMBR (0.63) | NPY1RNPY2RNPY4RNPY5RGLP1R | |
| SCHEMBL14930600 | 0.87 | NMBR (0.58) | NPY1RNPY2RNPY4RNPY5RGLP1R | |
| SCHEMBL25845686 | 0.87 | NMBR (0.58) | NPY1RNPY2RNPY4RNPY5RGLP1R | |
| SCHEMBL14930601 | 0.87 | NMBR (0.58) | NPY1RNPY2RNPY4RNPY5RGLP1R | |
| SCHEMBL25845917 | 0.86 | NMBR (0.66) | NPY1RNPY2RNPY4RNPY5RGLP1R | |
| SCHEMBL25845909 | 0.86 | NMBR (0.66) | NPY1RNPY2RNPY4RNPY5RGLP1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11191843-B2 | Multi-arm targeting anti-cancer conjugate | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2021-12-07 | — | — | US | disclosed |
| US-20210008218-A1 | MULTI-ARM TARGETING ANTI-CANCER CONJUGATE | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2021-01-14 | — | — | US | disclosed |
| US-10869863-B2 | Multi-arm polymeric targeting anti-cancer conjugate | BRIGHTGENE BIO-MEDICAL TECHNOLOGY CO., LTD. (CN) | 2020-12-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210008218-A1 | MULTI-ARM TARGETING ANTI-CANCER CONJUGATE | DCLRE1A, RRP12, LARP1 | NPY1R 992/4885NPY2R 1855/4885NPY4R 2182/4885 |
| US-11191843-B2 | Multi-arm targeting anti-cancer conjugate | LCP1, RRP12, PHLPP1 | NPY1R 755/4885NPY2R 1144/4885NPY4R 1638/4885 |
| US-10869863-B2 | Multi-arm polymeric targeting anti-cancer conjugate | TOP2A, TOP1, ABCG2 | NPY1R 4604/4885NPY2R 4531/4885NPY4R 4409/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.